Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
Express Scripts
Harvard Business School
McKinsey

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR AZILECT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Azilect

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00399477 ↗ A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease Completed Teva Neuroscience, Inc. Phase 4 2006-10-01 Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: - Group 1 Patients using Azilect and no other therapy. - Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
NCT00696215 ↗ The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status Istanbul University Phase 4 2007-06-01 The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain.
NCT00936676 ↗ ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Completed H. Lundbeck A/S 2009-07-01 Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status).
NCT00936676 ↗ ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Completed Teva Neuroscience, Inc. 2009-07-01 Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Azilect

Condition Name

Condition Name for Azilect
Intervention Trials
Parkinson's Disease 16
Parkinson Disease 3
Retinal Detachment 1
Serotonin Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Azilect
Intervention Trials
Parkinson Disease 22
Cognitive Dysfunction 2
Cognition Disorders 2
Malignant Carcinoid Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Azilect

Trials by Country

Trials by Country for Azilect
Location Trials
United States 57
Canada 9
Germany 6
Israel 4
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Azilect
Location Trials
New York 5
Florida 5
Ohio 4
California 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Azilect

Clinical Trial Phase

Clinical Trial Phase for Azilect
Clinical Trial Phase Trials
Phase 4 10
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Azilect
Clinical Trial Phase Trials
Completed 18
Terminated 4
Unknown status 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Azilect

Sponsor Name

Sponsor Name for Azilect
Sponsor Trials
Teva Branded Pharmaceutical Products R&D, Inc. 8
Teva Pharmaceutical Industries 8
Teva Neuroscience, Inc. 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Azilect
Sponsor Trials
Industry 33
Other 16
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Dow
Johnson and Johnson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.